Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix

Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix
Cellceutix announced additional interim positive findings from its ongoing Phase 2a trial evaluating brilacidin (PMX-30063) as a treatment for two types of inflammatory bowel disease (IBD) – ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). The proof-of-concept, open-label, dose-escalation trial is designed to evaluate the effectiveness, safety and drug properties of three dosing regimens of brilacidin – 50 mg (cohort A), 100

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Kathleen Williams says:

    How can I get treatment for my IBS. My doctor will not even refer me to a GI specialist. I am also a celiac.

Leave a Comment

Your email address will not be published. Required fields are marked *